has announced the conclusion of its acquisition of clinical-stage biopharmaceutical company . Fusion specialises in the development of next-generation radioconjugates (RCs) for cancer treatment. The gold standard of business intelligence.
The acquisition is expected to help AstraZeneca transform cancer therapy by introducing more targeted treatments. A resulted in AstraZeneca, through a subsidiary, acquiring all outstanding shares of Fusion for $21.00 per share in cash at closing.
A non-transferable contingent value right of $3 per share is payable upon reaching a specified regulatory milestone before 31 August 2029. The upfront payment and maximum potential contingent value payment take the transaction value to $2.4bn.
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form AstraZeneca has acquired Fusion’s cash, cash equivalents and short-term investments, which totalled $211m as of 31 March 2024. Fusion now operates as a wholly owned AstraZeneca subsidiary, with operations continuing in Canada and the US.
The move aligns with AstraZeneca’s plan to enhance cancer treatment and patient outcomes by replacing traditional chemotherapy and radi.
